Wegovy Tablets / semaglutide

Wegovy Tablets refers to an oral semaglutide treatment option for weight management. It is different from the Wegovy injection pen and its suitability, dosing and instructions need separate clinical review.

Availability for new patients depends on Keltoi's current catalogue and clinical governance. Treatment is never supplied unless a prescriber decides it is appropriate.

Semaglutide acts on GLP-1 pathways involved in appetite and fullness.

For weight management, it is used alongside diet and physical activity advice and should not be viewed as a stand-alone or guaranteed treatment.

This is an oral tablet presentation rather than an injection pen.

Patients should follow the exact instructions supplied with the medicine and any advice from their prescriber or pharmacist, including timing and food or drink instructions where relevant.

It may be considered for adults living with obesity, or overweight with weight-related health problems, where a clinician decides the benefits and risks are appropriate.

A clinician will consider whether an oral option is appropriate for the individual, including medical history, current medicines, preferences and practical use.

Semaglutide may not be suitable for people who are pregnant, planning pregnancy, breastfeeding, or who have certain health conditions.

People with a history of serious allergic reaction to semaglutide or related medicines, pancreatitis concerns, complex diabetes treatment or significant gastrointestinal symptoms may need additional review or a different approach.

Common side effects of semaglutide can include nausea, vomiting, diarrhoea, constipation, abdominal discomfort, indigestion, headache and tiredness.

Side effects vary between people and should be discussed with a healthcare professional if they are severe, persistent or worrying.

This page is a draft for clinical review and is not a substitute for advice from a prescriber, pharmacist or another healthcare professional.

A clinician will consider your health history, current medicines, pregnancy plans, allergies and any relevant symptoms before deciding whether treatment is appropriate.

Seek urgent medical advice if you develop symptoms that may suggest a serious reaction, such as severe abdominal pain, signs of an allergic reaction, severe dehydration or sudden changes in vision.

Semaglutide should not be used during pregnancy or breastfeeding.

People who could become pregnant should discuss contraception and pregnancy plans with their clinician. UK public health advice says semaglutide should be stopped for a period before trying to conceive.

Tell the prescriber about all medicines, supplements and herbal products you use.

Extra review may be needed for people using insulin, other diabetes medicines, warfarin, levothyroxine or medicines affected by changes in digestion.

Because this is an oral medicine, the prescriber may need to consider timing and absorption alongside other tablets.

If treatment is considered, you would complete Keltoi's existing weight management assessment.

A prescriber reviews the information you provide and may ask for more detail before making any prescribing decision.

Treatment is only prescribed where the clinician decides it is clinically appropriate.